Nalbuphine hydrochloride ER is a Small Molecule owned by Trevi Therapeutics, and is involved in 13 clinical trials, of which 8 were completed, 3 are ongoing, and 2 are planned.

Nalbuphine hydrochloride ER (T-111) is an opioid analgesic with mixed opioid agonist and antagonist activity. It acts as kappa agonist and partial mu antagonist. Pruritus is a recognized adverse reaction in patients receiving opioids. The drug candidate inhibits the ascending pain pathways, altering the perception of and response to pain by binding to opiate receptors in the CNS. It also produces generalized CNS depression. The drug candidate checks the progression of disease by modulating the receptor.

The revenue for Nalbuphine hydrochloride ER is expected to reach a total of $2.2bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Nalbuphine hydrochloride ER NPV Report.

Nalbuphine hydrochloride ER is currently owned by Trevi Therapeutics.

Nalbuphine hydrochloride ER Overview

Nalbuphine hydrochloride ER (T-111) is under development for the treatment of chronic pruritus in prurigo nodularis, pruritis in chronic liver disease, chronic cough in idiopathic pulmonary fibrosis patients and levodopa-induced dyskinesia (LID) in Patients with Parkinson’s Disease, uremic pruritus. The drug candidate is administered through oral route as a tablet. The drug candidate is an extended release formulation of an existing compound nalbuphine hydrochloride. Nalbuphine is a phenanthrene derivative which targets opioid kappa and mu receptors and it was also under development for the treatment of atopic dermatitis. It was also under development for atopic dermatitis.

Trevi Therapeutics Overview

Trevi Therapeutics, Inc. (Trevi Therapeutics), is a clinical-stage biopharmaceutical company that develops nalbuphine ER to treat neurologically mediated conditions by targeting central and peripheral nervous systems. It offers product Haduvio™ which uses for the treatment of serious cough conditions including IPF, interstitial lung diseases, and refractory chronic cough. The company offers nalbuphine ER as its pipeline product. Its product is being developed for treating patients with prurigo nodularis, pruritus in chronic liver disease, chronic cough related to idiopathic pulmonary fibrosis (IPF) and levodopa-induced dyskinesia (LID). It operates across the US. Trevi Therapeutics is headquartered in New Haven, Connecticut, the US.

The operating loss of the company was US$32.5 million in FY2021, compared to an operating loss of US$32.5 million in FY2020. The net loss of the company was US$33.9 million in FY2021, compared to a net loss of US$32.8 million in FY2020.

Quick View – Nalbuphine hydrochloride ER

Report Segments
  • Innovator
Drug Name
  • Nalbuphine hydrochloride ER
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Dermatology
  • Gastrointestinal
  • Respiratory
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.